

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA – Afatinib for treating epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

A potential equality issue was raised at the scoping workshop regarding the availability of timely EGFR testing to influence first line therapy. Workshop attendees discussed that some trusts do not routinely perform EGFR testing before commencing treatment.

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

Workshop attendees discussed how EGFR testing was becoming quicker and integrated into standard NHS practice and that the numbers who weren't tested to inform treatment decisions were reducing with time. It was also felt that this was an equity issue in terms of potential access to afatinib rather than a specific equalities issue.
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

None

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Helen Knight

Date: 31/05/2013